Search Clinical Trials
Not Yet Recruiting
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells (External Link)
The study team will collect up to 18 teaspoons of patients' blood. This will be used this blood to grow T cells. The study team then grows the T cells …
Baylor Role:
Lead Sponsor
Not Yet Recruiting
Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (External Link)
Approximately 15-24 subjects will participate in the treatment part of this study. Maximum of 180 mL of blood (not exceeding 3ml/kg/day) is collected from patients to grow the T cells …
Baylor Role:
Lead Sponsor
Not Yet Recruiting
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas (External Link)
This is a dose escalation study. This means that at the beginning, patients will be started on the lowest dose (1 of 4 different levels) of C7R.CD30.CAR-EBVST cells. Once the …
Baylor Role:
Lead Sponsor
Not Yet Recruiting
CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY) (External Link)
Patients will be enrolled to this study in two treatment groups: C7R-EBVSTs without lymphodepletion (Group A) and C7R-EBVSTs with lymphodepletion (Group B). The investigators will enroll patients into group B …
Baylor Role:
Lead Sponsor
Not Yet Recruiting
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma (External Link)
Study Design: The study will be a two-arm, randomized non-comparative Phase Ib/IIa study of induction dual immunotherapy with durvalumab/tremelimumab OR platinum chemotherapy (cisplatin or carboplatin) and pemetrexed chemotherapy plus dual …
Baylor Role:
Lead Sponsor